Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 476-482

  Bokemeyer, Bernd ^a,b   Hommes, Daan ^c   Gill, Ivo ^d   Broberg, Per ^e   Dignass, Axel ^f  

^a KLINIKUM MINDEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Nemocnice   (Czech Republic)

^e Ferring Pharmaceuticals AS   (Denmark)

^f AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

5 ASA; Left sided; Mesalazine; Mucosal healing; Ulcerative colitis

Indexed keywords

MESALAZINE;

ABDOMINAL PAIN; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPY; FLATULENCE; GASTROENTERITIS; HEALING; HUMAN; INTESTINE MUCOSA; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SINUSITIS; TIMED DRUG RELEASE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; COLON; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESALAMINE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860149749     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.006     Document Type: Article

References (35)

1. Moum B., Ekbom A., Vatn M.H., Aadland E., Sauar J., Lygren I., et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997, 32:1005-1012.
2. Timmer A., Goebell H. Incidence of ulcerative colitis 1980-1995. A prospective study in an urban population in Germany. Z Gastroenterol 1999, 37:1079-1084.
3. Travis S.P., Stange E.F., Lémann M., Oresland T., Bemelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2:24-62.
4. Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin Gastrointest Dis 2001, 12:263-274.
5. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
6. Osterwald H.P. Pharmaceutical development. Scand J Gastroenterol Suppl 1990, 172:43-46.
7. Brynskov J., Rasmussen S.N. Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Scand J Gastroenterol 1996, 216:175-180.
8. Keller J., Goebell H., Klotz U., Layer P. Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen. Med Klin 1998, 93:294-299.
9. Rochester J., Abreu M.T. Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord 2005, 5:215-222.
10. Ewe K., Schwartz S., Petersen S., Press A.G. Inflammation does not decrease intra-luminal pH in chronic inflammatory bowel disease. Dig Dis Sci 1999, 44:1434-1439.
11. Raimundo A.H., Evans D.F., Rogers J., Silk D.B.A. Gastrointestinal pH profiles in ulcerative colitis. Gastroenterology 1992, 102:A681.
12. Nugent S.G., Rampton D.S., Kumar D. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH dependent 5-ASA containing capsules (abstract T34). Gut 2000, 47(Suppl. 2):A9.
13. Christensen L.A., Fallingborg J., Abildgaard K., Jacobsen B.A., Sanchez G., Hansen S.H., et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990, 4:523-533.
14. Dignass A.U., Bokemeyer B., Adamek H., Mross M., Vinter-Jensen L., Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:762-769.
15. Bokemeyer B., Dignass A., Stijnen T., Veerman H. P169 - higher remission rates in patients with once-daily dosing compared to twice daily-dosing. An analysis of compliance in the once-daily vs. twice-daily PODIUM trial with mesalazine (Pentasa®) sachets. J Crohns Colitis 2009, 3:S78.
16. Regueiro M., Loftus E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979-994.
17. Prantera C., Kohn A., Campieri M., Caprilli R., Cottone M., Pallone F., et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009, 30:908-918.
18. Marteau P., Probert C.S., Lindgren S. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
19. Marshall J.K., Irvine E.J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000, 95:1628-1636.
20. Nugent S.G., Kumar D., Rampton D.S., Evans D.F. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001, 48:571-577.
21. Lawrance I.C. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol 2011, 26(1):36-43.
22. Kruis W., Jonaitis L., Pokrotnieks J., Mikhailova T.L., Horynski M., Bátovský M., et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011, 33:313-322.
23. Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008, 57:893-902.
24. Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
25. Ochsenkühn T., D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011, 60:1294-1299.
26. Kane S., Lu F., Kornbluth A. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009, 15:796-800.
27. Hanauer S.B., Sandborn W.J., Kornbluth A., Katz S., Safdi M., Woogen S., et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005, 100:2478-2485.
28. Hanauer S.B., Sandborn W.J., Dallaire C., Archambault A., Yacyshyn B., Yeh C., et al. Delayed-release oral mesalamine 4.8g/day (800mg tablets) compared to 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007, 21:827-834.
29. Hanauer S.B., Sandborn W.J., Dallaire C., Archambault A., Yacyshyn B., Yeh C., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132:66-75.
30. Lichtenstein G.R., Kamm M.A., Boddu P., Gubergrits N., Lyne A., Butler T., et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007, 5:95-102.
31. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
32. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
33. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422. IBSEN Group.
34. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53:1813-1816.
35. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med 1990, 323:1228-1233.